Phase 2 N=68 Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Breast Cancer
Primary: Bone Scan Response Rate — 38.5 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 FMT in Cirrhosis and Hepatic Encephalopathy
Cirrhosis · Hepatic Encephalopathy
Primary: Serious Adverse Events Related to FMT — 0; 0; 0; 0 Participants
N/A N=48 Scavenging of Reactive Carbonyl Species by Dietary Flavonoids in Humans
Human Health · Reactive Carbonyl Species · Polyphenols
Primary: Change in Urinary Levels of Reactive Carbonyl Species (RCS) of Soymilk, Green Tea, or Blueberry Over 8 Hours After One Single Dose of Soymilk, Green Tea, or Blueberry…
Phase 3 N=804 Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
Alzheimer Disease
Primary: Change From Baseline in the 12-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog12) — 2.79; 3.19 score on a scale — p=0.4308
N/A N=33 Virtual Reality for Outpatient Cancer Pain Management
Cancer · Cancer Pain
Primary: Self-reported Pain Score — -0.3 score on a scale, measured each week
N/A N=175 Non-Invasive Cooling of Fat Cells
Reduction of Unwanted Fat
Primary: Percentage of Participants With Visible Improvement in Treated Area — 65.2; 82.8 percentage of participants
Phase 2 N=30 Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
Glioblastoma Multiforme of Brain
Primary: Safety and Tolerability — 19; 2; 2; 2 participants
N/A N=396,983 Tianjin Diabetes and Health Cohort Study
Diabetes Mellitus
Primary: Diabetes Complications — 10263; 97864; 59029; 69822 Participants
N/A N=174 Shared-Decision Making for Hydroxyurea
Sickle Cell Anemia · Children, Only
Primary: Decisional Conflict — 22.9; 19.8; 26.9; 23.5 score on a scale
Phase 3 N=217 A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
SARS-CoV-2
Primary: Geometric Mean (GM) Value of Neutralizing Antibodies (nAbs) Against SARS-CoV-2-specific Strain at Day 15 — 1180.55; 1300.25 AU/mL
Phase 2 N=43 Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection
Clostridioides Difficile Infection
Primary: Rate of Clinical Cure at the Test of Cure [TOC] Visit in the Intent-to-treat [ITT] Population — 13; 15; 13; 0 Participants
N/A N=445 Tailoring Online Continence Promotion
Urinary Incontinence in Old Age · Fecal Incontinence in Old Age
Primary: User Engagement With Online Mind Over Matter (MOM) — 17; 37 Participants
N/A N=50 Forensic-medical Aspects of Lower Limb Prosthetics: An Observational Study
Amputation
Primary: Questionnaire: Trinity Amputation Prosthesis Experience Scale (TAPES) — 57; 8; 40 units on a scale
Phase 2 N=374 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Squamous Cell Carcinoma of Head and Neck
Primary: Overall Survival (OS) — 8.4; 11.3 Months — p=0.9963
Phase 2 N=79 Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection
Recurrent Clostridium Difficile Infection · Clostridium Difficile Infection · CDI
Primary: Recurrent Clostridium Difficile Infection (CDI) — 17; 24 Participants — p=0.22